$NRIX News
Last published 14h ago
- 14h agoNRIXNurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical OfficerGlobeNewswirePhysician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions
- 6d agoNRIXNurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and ExpositionGlobeNewswireBRISBANE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 1w agoNRIXNurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272GlobeNewswireBRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi
- 1mo agoNRIXNurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireDosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiting
- 1mo agoNRIXNurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic LeukemiaGlobeNewswireFirst patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg
- 2mo agoNRIXNurix Therapeutics to Participate in Upcoming September Investor ConferencesGlobeNewswireBRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 2mo agoNRIXNurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources OfficerGlobeNewswireBRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients with cancer and
- 3mo agoNRIXNurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 DegraderGlobeNewswireOral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive
- 3mo agoNRIXNurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaGlobeNewswireBRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 study (NCT07516093) evaluating
- 3mo agoNRIXNurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and NeurologyGlobeNewswireBRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 5mo agoNRIXNurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of TherapyGlobeNewswireHigh objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median progression-free
- 5mo agoNRIXRHHBYNurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and NeurologyGlobeNewswireStrategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clinical development
- 5mo agoNRIXRHHBYRoche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurologyGlobeNewswireAgreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential indications in immunology
- 6mo agoNRIXNurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual MeetingGlobeNewswireIn preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteers, both single- and
- 6mo agoNRIXNurix Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireBRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 6mo agoNRIXNurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association CongressGlobeNewswireBRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 6mo agoNRIXNurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026GlobeNewswireData showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand therapeutic reach
- 7mo agoNRIXNurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateGlobeNewswireEnrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg confirmatory
- 7mo agoNRIXNurix Therapeutics to Participate in Upcoming Investor ConferenceGlobeNewswireBRISBANE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 7mo agoNRIXNurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual MeetingGlobeNewswireBRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 9mo agoNRIXNurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate UpdateGlobeNewswireFirst patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile in
- 10mo agoONCYNRIXERASFHTX+1Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent CliffPR NewswireEquity-Insider.com News Commentary – The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion toward a...
- 10mo agoNRIXNurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune DiseasesGlobeNewswireExecute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia (r/r
- 10mo agoNRIXNurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBRISBANE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 10mo agoCRBUGTBPLYELNRIX+1Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market SurgeGlobeNewswireVANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a
- 11mo agoNRIXNurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and ExpositionGlobeNewswireObjective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median duration of response
- 11mo agoNRIXNurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & ExpositionGlobeNewswireObjective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data from randomized
- 11mo agoNRIXNurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and ExpositionGlobeNewswireSAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 11mo agoNRIXNurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireSAN FRANCISCO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 1y agoNRIXNurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of DirectorsGlobeNewswireSAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 1y agoNRIXNurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment RemodelingGlobeNewswireSAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies to treat cancer and immune disorders,
- 1y agoNRIXNurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual MeetingGlobeNewswireSAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 1y agoNRIXNurix Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 1y agoNRIXNurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common StockGlobeNewswireSAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein
- 1y agoNRIXNurix Therapeutics Announces $250.0 Million Registered Offering of Common StockGlobeNewswireSAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 1y agoNRIXNurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic LeukemiaGlobeNewswire600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential
- 1y agoNRIXNurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) CongressGlobeNewswireNX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 demonstrated evidence of
- 1y agoGTBPNRIXGRALCCCC+1Precision Oncology Approaches Drive $312B Market TransformationPR NewswireUSA News Group News Commentary – Biomarker-driven drug development accelerates across oncology as companies advance novel mechanisms targeting...
- 1y agoNRIXNurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate UpdateGlobeNewswireAnnounced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a novel IRAK4
- 1y agoNRIXNurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of DermatitisGlobeNewswireData support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers is ongoing Data are being presented at the European Academy of
- 1y agoNRIXNurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)Earnings Call Transcripts
- 1y agoNRIXNurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript)Earnings Call Transcripts
- 1y agoNRIXNurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptEarnings Call Transcripts
- 1y agoNRIXNurix Therapeutics, Inc. (NRIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoNRIXNurix Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 1y agoNRIXEuropean Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström MacroglobulinemiaGlobeNewswireSAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 1y agoNRIXNurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 1y agoNRIXNurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)GlobeNewswireComplete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study
- 1y agoNRIXNurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)GlobeNewswireSAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
- 1y agoNRIXSanofi Exercises License Extension Option to Nurix's STAT6 ProgramGlobeNewswireSTAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi under its 2019